I was able to listen the first three abstracts presented before I left for the airport.
You may search the abstracts available online at https://abstracts.asco.org/239/IndexView_239.html
for information on the other studies presented during that session.
5503 NACT compared to chemoradiation in cervical cancer
5504 Recurrence rates in cervical cancer abdominal vs minimally invasive surgery
5505 Niraparib and Bev vs niraparib alone in recurrent plat sensitive OC
5506 Olaparib monotherapy vs chemo for germline BRCA plat sensitive relapsed OC
5507 CLIO study on olaparib monotherapy vs chemo in plat sensitive OC
5508 EWOC-1 Three different first line chemo regimens for vulnerable elderly women with OC
5500 Powell - Ph 3 Paclitaxel + carbo vs Paclitaxel + ifosfamidein chem naive patientswith carincosarcomea of the uterus or ovary
.@matthewapowell Paclitaxel-carboplatin is not inferior to ifos-paclitaxel in carcinosarcomas of the #ovary and #uterus in terms of OS (and maybe superior in terms of PFS) This establishes a new standard of care! #gyncsm #ASCO19 pic.twitter.com/BwABZhNCnv— Shannon Westin (@ShannonWestin) June 3, 2019
— Dee Sparacio (@womenofteal) June 3, 20195501 Antill - Duralumab in adv endometrial cancer accroding to mismatch repare status PHAEDRA Study
Durvalumab is active in MMR deficient #EndometrialCancer with 43% response rate which is quite durable! Minimal activity in MMR intact disease. #gyncsm #ASCO19 pic.twitter.com/2swdfKRIFB— Shannon Westin (@ShannonWestin) June 3, 2019
— Dee Sparacio (@womenofteal) June 3, 20195502 Konstantinopoulos Ph2 avelumab in patients with microsatellite stable(MSS) ,microsatellite instable (MSI) and polymerase epsilon mutated (POLE)recurent endometrial cancer
Dr Konstantinopoulas discussed Avelumab #ASCO19 pic.twitter.com/NYCJBbsTx9— Dee Sparacio (@womenofteal) June 3, 2019
My last post on ASCO19 will be about the Opening session.
Dee
Every Day is a Blessing!
No comments:
Post a Comment